Karis Little

Dr. Karis Little

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
MLMaría Llorián-Salvador
María Llorián-Salvador
EBEimear M. Byrne
Eimear M. Byrne
MSManon Szczepan
Manon Szczepan
KLKaris Little
Karis Little
MCMei Chen
Mei Chen
Heping XuHeping Xu
Heping Xu
Background: We previously reported higher plasma levels of complement fragments C3a and C5a in neovascular Age-related Macular Degeneration (nAMD) patients with macular fibrosis. This study aimed to understand whether complement activation contributes to the development of macular fibrosis and the underlying mechanisms involved. Methods: Complement activation was blocked using a C5 neutralizing antibody (BB5.1) in C57BL/6J mice after induction of subretinal fibrosis using the two-stage laser protocol. Fibrotic lesions were examined 10 days after the 2nd laser through fundus examination and immunohistochemistry. The expression of C5aR in fibrotic lesions and retinal pigment epithelial (RPE) cultures were examined by confocal microscopy. Primary murine RPE cells were treated with C3a or C5a (10–100 ng/mL) or TGF-β2 (10 ng/mL). Epithelial-to-mesenchymal transition (EMT) was assessed through various readouts. The expression of E-cadherin, vimentin, fibronectin, α-SMA, Slug, ERK/AKT and pSMAD2/3 were determined by Western blot and immunocytochemistry. Collagen contraction and wound-healing assays were used as functional readouts of EMT. The production of IL-6, TGF-β1, TGF-β2 and VEGF by RPE cells were determined by ELISA. PMX53 was used to block C5aR in RPE cultures and in vivo in mice with subretinal fibrosis. Results: Extensive C5b-9 deposition was detected at the site of subretinal fibrosis. BB5.1 treatment completely abrogated complement activation and significantly reduced subretinal fibrosis. C5aR was detected in RPE and infiltrating MHC-II+ cells in subretinal fibrosis. In vitro, RPE cells constitutively express C5/C5a and C5aR, and their expression was increased by TGF-β2 treatment. C5a but not C3a increased fibronectin, α-SMA, vimentin and Slug expression, and decreased E-cadherin expression in RPE cells. C5a treatment also increased the contractility and migration of RPE cells and enhanced the production of VEGF and TGF-β1/2. C5a treatment induced pSmad2/3 and pERK1/2 expression in RPE cells and this was blocked by PMX53. PMX53 treatment significantly reduced sodium fluorescein leakage in the subretinal fibrosis model, while collagen-I+ lesions only mildly reduced. Conclusions: Complement activation is critically involved in the development of subretinal fibrosis, partially through C5a–C5aR-mediated EMT in RPE cells. Targeting complement activation rather than C5a may be a novel approach for the management of macular fibrosis.

21 July 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
BKBurak Mugdat Karan
Burak Mugdat Karan
KLKaris Little
Karis Little
JAJosy Augustine
Josy Augustine
Alan W StittAlan W Stitt
Alan W Stitt
TCTim M Curtis
Tim M Curtis
Diabetic retinopathy (DR) is a complication of diabetes mellitus that can lead to vision loss and blindness. It is driven by various biochemical processes and molecular mechanisms, including lipid peroxidation and disrupted aldehyde metabolism, which contributes to retinal tissue damage and the progression of the disease. The elimination and processing of aldehydes in the retina rely on the crucial role played by aldehyde dehydrogenase (ALDH) and aldo-keto reductase (AKR) enzymes. This review article investigates the impact of oxidative stress, lipid-derived aldehydes, and advanced lipoxidation end products (ALEs) on the advancement of DR. It also provides an overview of the ALDH and AKR enzymes expressed in the retina, emphasizing their growing importance in DR. Understanding the relationship between aldehyde metabolism and DR could guide innovative therapeutic strategies to protect the retina and preserve vision in diabetic patients. This review, therefore, also explores various approaches, such as gene therapy and pharmacological compounds that have the potential to augment the expression and activity of ALDH and AKR enzymes, underscoring their potential as effective treatment options for DR.

1 January 2025 in Journal of Alzheimer's Disease Reports
Verified
Journal Article
Open access
SASurabhi D Abhyankar
Surabhi D Abhyankar
KLKaris Little
Karis Little
Alan W StittAlan W Stitt
Alan W Stitt
ABAshay Bhatwadekar
Ashay Bhatwadekar
Alzheimer's disease (AD) is a neurodegenerative condition manifesting as cognitive decline, memory deterioration, and behavioral alterations. Late-onset AD accounts for most diagnosed cases, with the onset of symptoms usually occurring after 65 years. At present, there are no proven treatments that alter the course of AD. For early detection and intervention, it is crucial to understand the underlying mechanisms and identify promising biomarkers for AD. Research suggests that the pathological processes of AD initiate years before the emergence of noticeable symptoms, which makes the early diagnosis more challenging. While various biomarkers, such as cognitive tests, imaging, and biological markers in blood and cerebrospinal fluid, have been proposed for early detection, their reliability, as matched with symptomatic stages, varies significantly. As a component of the central nervous system, the retina has attracted attention as a potential site for studying AD-related changes. Studies from human and animal models have revealed structural, vascular, functional, and metabolic changes in the retina through the early phases of AD. Furthermore, advances in ophthalmic technologies have facilitated the identification and characterization of AD-related changes such as amyloid-β and tau-protein deposition. This review provides an overview and perspective on AD as they relate to the retina and highlights the importance of ocular changes as surrogates for understanding and diagnosing AD.

30 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
TGTom Alexander Gardiner
Tom Alexander Gardiner
KLKaris Little
Karis Little
Alan W StittAlan W Stitt
Alan W Stitt
During diabetic retinopathy (DR), cell death has been characterized in all of the major retinal cell types, but was observed initially in the microvasculature, particularly the mural cells: pericytes and vascular smooth muscle cells (VSMCs). Indeed, our ability to identify the mural cell corpses called “ghost cells” within the vascular basement membranes (BMs) in eyes of diabetic patients and animal models is indicative that removal of dead cells, or efferocytosis (EF), is dysfunctional during this disease. EF is the process whereby apoptotic cells are eliminated through phagocytic engulfment and digestion and is essential to maintain tissue integrity and immune homeostasis. The process occurs in three distinct phases: finding and recognition, engulfment, and digestion, under the direction of “find me” and “eat me” signals and a large array of their cognate receptors and bridging molecules. Efferocytosis can be performed by many cell types, but most efficiently by professional phagocytes, and with such rapidity that the process is extremely difficult to detect in healthy tissues. As delayed EF is a recognized cause of autoimmune and inflammatory disease, mural cell death in DR may create inflammatory foci in the neurovascular unit (NVU). Here we discuss the basic mechanisms of EF in the context of DR and the impact of diabetic metainflammation on EF effector cell dysfunction.

8 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TGTom Alexander Gardiner
Tom Alexander Gardiner
KLKaris Little
Karis Little
Alan W StittAlan W Stitt
Alan W Stitt
During diabetic retinopathy (DR), cell death has been characterized in all of the major retinal cell types but was observed initially in the microvasculature, particularly the mural cells: pericytes and vascular smooth muscle cells (VSMCs). Indeed, our ability to identify mural cell corpses called “ghost cells” within the vascular basement membranes (BMs) in eyes from diabetic patients and animal models, is indicative that removal of dead cells, or efferocytosis (EF), is dysfunctional during this disease. EF is the process whereby apoptotic cells are eliminated through phagocytic engulfment and digestion and is essential to maintain tissue integrity and immune homeostasis. The process occurs in three distinct phases: finding and recognition, engulfment and digestion, under the direction of “find me” and “eat me” signals and a large array of their cognate receptors and bridging molecules. Efferocytosis can be performed by many cell types, but most efficiently by professional phagocytes, and with such rapidity that the process is extremely difficult to detect in healthy tissues. As delayed EF is a recognized cause of autoimmune and inflammatory disease, mural cell death in DR may create inflammatory foci in the neurovascular unit (NVU). Here we discuss the basic mechanisms of EF in the context of DR and the impact of diabetic metainflammation on EF effector cell dysfunction.

4 October 2026 in Diabetic Medicine
Verified
Journal Article
Open access
KLKaris Little
Karis Little
JLJudith Lechner
Judith Lechner
GRGiulia De Rossi
Giulia De Rossi
TCTara Cullen
Tara Cullen
JPJennifer Perais
Jennifer Perais
Alan W StittAlan W Stitt
Alan W Stitt
Aims: Diabetic retinopathy (DR) is a sight‐threatening consequence of diabetes. DR disrupts cell‐to‐cell communication in the retinal neurovascular unit (NVU), impairing blood flow which leads to vascular complications. Here, we propose an integrated framework of DR pathogenesis in which impaired clearance mechanisms and accumulation of extracellular metabolic waste act in concert to drive NVU dysfunction. By integrating evidence across cellular and molecular domains, we aim to highlight how these early events set the stage for later complications, including diabetic macular oedema. Methods: We have examined and summarised the literature, synthesising evidence and providing a narrative review of the impact of diabetes on retinal clearance homeostasis. PubMed database was used to search for terms including diabetic retinopathy, neurovascular unit, clearance and extracellular waste. Results: Diabetes disrupts blood–retinal barrier integrity, alters retinal waste production and fluid homeostasis, and promotes the accumulation of misfolded and glycated proteins. However, these processes, despite being interdependent, have largely been considered in isolation. This review integrates the available evidence to identify impaired retinal clearance as a convergent mechanistic link between barrier dysfunction, altered fluid dynamics and extracellular waste accumulation in DR. It also highlights how the specific clearance pathways may contribute to disease progression and represent potential therapeutic targets. Conclusions: Failure of tissue homeostasis may represent a critical but underappreciated driver of progressive retinal NVU dysfunction during DR. In this context, extracellular waste accumulation is not merely a downstream consequence of retinopathic progression, but a potential initiating factor that links metabolic dysregulation to the breakdown of the blood–retinal barrier and disrupts retinal architecture.